Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ikuto, Tsukiyama"'
Autor:
Ichiro Arakawa, Yusuke Kurose, Hiroko Saito, Ikuto Tsukiyama, Masahiko Ando, Masayuki Takeuchi, Tadao Inoue, Sumiyo Tsukiyama, Etsuro Yamaguchi, Akihito Kubo, Masayuki Ejiri
Publikováno v:
Supportive Care in Cancer. 27:3749-3758
Neurokinin-1 receptor antagonist (NK1RA) is recommended to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly or moderately emetogenic chemotherapy (HEC or MEC, respectively). We previously reported that aprepitant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::578f0cf4996807ba26e2886376e799eb
https://doi.org/10.1007/s00520-019-04672-w
https://doi.org/10.1007/s00520-019-04672-w
Autor:
Yoshiaki Ikeda, Etsuro Yamaguchi, Yusuke Kurose, Sumiyo Tsukiyama, Shiori Hasegawa, Ichiro Arakawa, Masayuki Takeuchi, Masaki Sakuma, Hiroko Saito, Akihito Kubo, Tadao Inoue, Ikuto Tsukiyama, Masayuki Ejiri
Publikováno v:
Cancer Science
Chemotherapy‐induced nausea and vomiting (CINV) remains a major adverse event in cancer chemotherapy. Although aprepitant is effective in preventing CINV, an increment in financial burden for uniform use of aprepitant is a concern. The aim of the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b41600c91ff0df59f8ee6510ad188da8
https://doi.org/10.1111/cas.13736
https://doi.org/10.1111/cas.13736
Autor:
Kazushi Watanabe, Ikuto Tsukiyama, Hiroshi Matsushita, Yoshihiro Yamamoto, Akihiko Wakatsuki, Katsuhiko Matsuura
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 43:1880-1886
Aim Risk factors for cisplatin-induced nephrotoxicity (CIN) vary by population. This study aimed to assess risk factors for CIN in patients with gynecological cancer. Methods Patients who underwent cisplatin-based chemotherapy for gynecological cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27ef9b436c95b173698b9eb791dd628a
https://doi.org/10.1111/jog.13457
https://doi.org/10.1111/jog.13457
Autor:
Katsuhiko Matsuura, Kazushi Watanabe, Yoshihiro Yamamoto, Hiroshi Matsushita, Ikuto Tsukiyama, Akihiko Wakatsuki
Publikováno v:
YAKUGAKU ZASSHI. 137:79-82
Hypomagnesemia is one side effect in patients receiving cisplatin. However, there are few reports of cisplatin-induced hypomagnesemia in Japan. We retrospectively investigated the incidence of hypomagnesemia and nephrotoxicity in patients undergoing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c47316109e5d3f6089d17624413c428
https://doi.org/10.1248/yakushi.16-00185
https://doi.org/10.1248/yakushi.16-00185
Autor:
Katsuhiko Matsuura, Haruhisa Nakao, Yoshihiro Yamamoto, Masayuki Ejiri, Hiroko Saito, Ikuto Tsukiyama, Tadao Inoue, Ichiro Arakawa, Masashi Yoneda
Publikováno v:
Journal of Gastrointestinal Cancer
Objectives This study assessed the cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone for advanced biliary tract cancer (BTC) in Japan. Methods A monthly transmitted Markov model of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43da273d74837b54cb5736893867a37a
https://doi.org/10.1007/s12029-016-9885-6
https://doi.org/10.1007/s12029-016-9885-6
Autor:
Masayuki Ejiri, Tatsuya Hisada, Yuki Arakawa, Sachiko Koyama, Yumiko Sato, Kazuhiro Mori, Saori Gocho, Ikuto Tsukiyama, Yukari Itakura
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 42:185-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a518cf17e6f66d155dc116c660d106b
https://doi.org/10.5649/jjphcs.42.185
https://doi.org/10.5649/jjphcs.42.185
Autor:
Ikuto, Tsukiyama, Masahiko, Ando, Sumiyo, Tsukiyama, Masayuki, Takeuchi, Masayuki, Ejiri, Yusuke, Kurose, Hiroko, Saito, Ichiro, Arakawa, Tadao, Inoue, Etsuro, Yamaguchi, Akihito, Kubo
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(10)
Neurokinin-1 receptor antagonist (NKA decision-analytic model was developed according to the necessity of aprepitant and CINV responses in both acute and delayed phases of chemotherapy. Probabilities of health states and medical costs were derived fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2320130e6e4658f62c49fb76e7ce4eb
https://pubmed.ncbi.nlm.nih.gov/30710243
https://pubmed.ncbi.nlm.nih.gov/30710243
Publikováno v:
SANGYO EISEIGAKU ZASSHI. 57:275-285
OBJECTIVES Anti-cancer drugs are harmful to healthy persons. In recent years, occupational exposure to anti-cancer drugs has become a major concern to health care workers. To address this issue, a smear method was developed to measure widely using an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d8f077db3e8702364ae244e3a1378b
https://doi.org/10.1539/sangyoeisei.b15004
https://doi.org/10.1539/sangyoeisei.b15004
Autor:
Yoshihiro, Yamamoto, Kazushi, Watanabe, Hiroshi, Matsushita, Ikuto, Tsukiyama, Katsuhiko, Matsuura, Akihiko, Wakatsuki
Publikováno v:
The journal of obstetrics and gynaecology research. 43(12)
Risk factors for cisplatin-induced nephrotoxicity (CIN) vary by population. This study aimed to assess risk factors for CIN in patients with gynecological cancer.Patients who underwent cisplatin-based chemotherapy for gynecological cancer between Jan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c15ab0f7503da8d2c623db3b2b3742b0
https://pubmed.ncbi.nlm.nih.gov/28984058
https://pubmed.ncbi.nlm.nih.gov/28984058
Autor:
Hidetsugu Nagamatsu, Akiko Ban, Yuki Yoshioka, Yumiko Oshima, Tatsuya Hisada, Yukari Itakura, Etsuko Mishima, Mitsuhiro Mizutani, Ikuto Tsukiyama, Toshinori Sasaki, Kenji Katsuragawa
Publikováno v:
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 136(7)
It is often necessary to modify the dose or schedule of eribulin mesilate (Eri) because of adverse events. Therefore, we retrospectively investigated the optimal approach for Eri dose adjustment and/or dosage interval adjustment. Patients who receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a956a6cab9d93c195d2195b11d69c86
https://pubmed.ncbi.nlm.nih.gov/27040459
https://pubmed.ncbi.nlm.nih.gov/27040459